Who Generates Higher Gross Profit? AstraZeneca PLC or Supernus Pharmaceuticals, Inc.

AstraZeneca vs. Supernus: A Tale of Two Giants in Gross Profit

In the competitive world of pharmaceuticals, AstraZeneca PLC and Supernus Pharmaceuticals, Inc. have carved out significant niches. From 2014 to 2023, AstraZeneca consistently outperformed Supernus in terms of gross profit. In 2023, AstraZeneca's gross profit soared to nearly 38 billion, marking a staggering 86% increase from 2014. In contrast, Supernus, while showing growth, reached a gross profit of just over 524 million in 2023, a 350% increase from its 2014 figures. This stark difference highlights AstraZeneca's dominant market position, driven by its expansive product portfolio and global reach. Meanwhile, Supernus, with its focus on niche markets, has shown impressive growth percentages, albeit from a smaller base. This data underscores the diverse strategies and scales of operation within the pharmaceutical industry, offering insights into how different companies navigate market challenges and opportunities.